-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of July 26, WuXi AppTec, the CRO leader, disclosed its semi-annual repo.
The financial report shows that in the first half of this year, WuXi PharmaTech achieved operating income of 1756 billion yuan, a year-on-year increase of 652%; net profit attributable to the parent was 636 billion yuan, a year-on-year increase of 729%; the profit amount during the period has reached the highest in history for the same peri.
During the period, the revenue of the testing business, biology business, cell and gene therapy CTDMO business, and other business segments increased by 262%, 152%, 373%, and 729% respectively over the same period of the previous ye.
Reference: Corporate Announcement China Industrial Economic Information Network China Securities Journal
The financial report shows that in the first half of this year, WuXi PharmaTech achieved operating income of 1756 billion yuan, a year-on-year increase of 652%; net profit attributable to the parent was 636 billion yuan, a year-on-year increase of 729%; the profit amount during the period has reached the highest in history for the same peri.
During the period, the revenue of the testing business, biology business, cell and gene therapy CTDMO business, and other business segments increased by 262%, 152%, 373%, and 729% respectively over the same period of the previous ye.
R&D expenses increased by over 60%
In May 2018, WuXi AppTec was listed on the Shanghai Stock Exchan.
In 2021, WuXi PharmaTech's R&D investment will be 940 million yuan, and R&D investment will account for 11% of operating income during the same peri.
In the first half of 2022, WuXi PharmaTech's R&D expenses were 660 million yuan, a year-on-year increase of 6
Multiple companies pre-increase
A number of A-share CXO companies have disclosed their performance forecasts for the first half of 202 Proton, Asymchem, and Zhaoyan New Drug are expected to double their net profit attributable to their parent compani.
The overall performance of CXO companies in the first half of the year was good, and some companies expected that the net profit in the second quarter would hit a record high in a single quart.
Proton shares predicts that in the first half of the year, the net profit attributable to the parent is 191 billion yuan to 212 billion yuan, an increase of 455% to 465% year-on-year, and the growth rate is among the highe.
Asymchem expects to achieve a net profit of 644 billion yuan to 743 billion yuan in the first half of the year, a year-on-year increase of 2899% to 3079.
Zhaoyan New Drug estimates that the net profit attributable to shareholders of listed companies in the first half of the year is 341 million yuan to 402 million yuan, an increase of about 128% to 168% year-on-ye.
The profit growth rate of Kanglong Chemical has slowed do.
Reference: Corporate Announcement China Industrial Economic Information Network China Securities Journal
